NASDAQ:CHEK

Check-Cap (CHEK) Stock Price, News & Analysis

$2.22
-0.06 (-2.63%)
(As of 04/29/2024 ET)
Today's Range
$2.20
$2.29
50-Day Range
$1.87
$3.11
52-Week Range
$1.27
$4.63
Volume
9,094 shs
Average Volume
204,009 shs
Market Capitalization
$12.99 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
CHEK stock logo

About Check-Cap Stock (NASDAQ:CHEK)

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation. Check-Cap Ltd. was incorporated in 2004 and is based in Isfiya, Israel.

CHEK Stock Price History

CHEK Stock News Headlines

StockNews.com Initiates Coverage on Check-Cap (NASDAQ:CHEK)
Elon’s New A.I. Device is About to Shock the World
Using this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.”
Why Is Check-Cap (CHEK) Stock Up 44% Today?
Larger than expected salary cap means more space for Jaguars
Elon’s New A.I. Device is About to Shock the World
Using this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.”
Check Cap Ltd (CHEK)
SYMETRYX COMMENTS ON SUCCESSFUL CAMPAIGN AT CHECK-CAP LTD
Check-Cap Board of Directors Issues Letter to Shareholders
Check-Cap: Q3 Earnings Insights
Check-Cap GAAP EPS of -$0.44
Check-Cap Posts Narrower Loss In Q3 - Quick Facts
Check-Cap Ltd CHEK
Notice of Extraordinary General Meeting of Shareholders
Kazakhstan Aims to Cut Loan-Rate Cap
See More Headlines
Receive CHEK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Check-Cap and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/27/2023
Today
4/30/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
X - ray apparatus & tubes
Sub-Industry
N/A
Current Symbol
NASDAQ:CHEK
Employees
85
Year Founded
N/A

Profitability

Net Income
$-19,110,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$8.57 per share

Miscellaneous

Free Float
5,822,000
Market Cap
$12.99 million
Optionable
Not Optionable
Beta
0.27
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Mr. Alex Ovadia (Age 62)
    CEO & Director
    Comp: $409.35k
  • Dr. Yoav Kimchy Ph.D. (Age 63)
    Founder & Interim CTO
    Comp: $362.65k
  • Mr. Joshua Belkar (Age 55)
    Vice President of Operations
    Comp: $269.57k
  • Ms. Iris Even-Tov
    Interim Chief Financial Officer
  • Ms. Noa Reshef M.B.A.
    Director of Human Resources

CHEK Stock Analysis - Frequently Asked Questions

Should I buy or sell Check-Cap stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Check-Cap in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" CHEK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CHEK, but not buy additional shares or sell existing shares.
View CHEK analyst ratings
or view top-rated stocks.

How have CHEK shares performed in 2024?

Check-Cap's stock was trading at $2.08 at the beginning of the year. Since then, CHEK shares have increased by 6.7% and is now trading at $2.22.
View the best growth stocks for 2024 here
.

Are investors shorting Check-Cap?

Check-Cap saw a decrease in short interest in April. As of April 15th, there was short interest totaling 131,100 shares, a decrease of 78.2% from the March 31st total of 600,000 shares. Based on an average daily volume of 251,300 shares, the short-interest ratio is currently 0.5 days. Approximately 3.0% of the company's stock are short sold.
View Check-Cap's Short Interest
.

When is Check-Cap's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our CHEK earnings forecast
.

How were Check-Cap's earnings last quarter?

Check-Cap Ltd. (NASDAQ:CHEK) released its earnings results on Monday, November, 27th. The medical research company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($0.83) by $0.39.

When did Check-Cap's stock split?

Check-Cap's stock reverse split on the morning of Friday, November 25th 2022. The 1-20 reverse split was announced on Friday, November 25th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, November 25th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Check-Cap own?
When did Check-Cap IPO?

Check-Cap (CHEK) raised $13 million in an IPO on Thursday, February 19th 2015. The company issued 1,200,000 shares at $10.00-$12.00 per share. Chardan Capital Markets and Maxim Group acted as the underwriters for the IPO and Feltl and Company was co-manager.

How do I buy shares of Check-Cap?

Shares of CHEK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CHEK) was last updated on 4/30/2024 by MarketBeat.com Staff

From Our Partners